About Abgenix
Abgenix is a Healthcare company based in Fremont (United States) founded in 1996, and was acquired by Amgen in December 2005. Fully human therapeutic antibodies for cancer and inflammation are discovered. Abgenix has completed 1 acquisition, including ImmGenics Pharmaceuticals. Abgenix offers products and services including Pancreatic Cancer Drugs, Zika Virus Vaccines, and Cancer Treatments. Its focus areas include Life Sciences, Immunotherapy, Antibody and Disease-Targeting. Its competitors include BeiGene, Moderna and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
Abgenix was a biopharmaceutical company focused on the discovery of fully human therapeutic antibodies for cancer and inflammatory diseases. Its products include Panitumumab, co-developed by Amgen is an IgG2 MAb which targets the epidermal growth factor receptor (EGFr), a protein that plays a role in cancer cell signaling. Its other product Denosumab is designed to target RANK Ligand, a protein that acts as the primary signal to promote bone removal. It claims to have potential in the treatment of a broad range of bone loss conditions including osteoporosis, treatment-induced bone loss, bone metastases, multiple myeloma, and rheumatoid arthritis. In December 2005, Amgen acquired Abgenix for around 2.2B.
- Headquarters Fremont, United States
- Stage Acquired
- SectorsHealthcare
- Website abgenix.com
- Social LinkedIn
- Acquired by Amgen (Dec 2005)
- Investors
- Investments & Acquisitions
- Acquired byAmgen
(Dec 2005)
Products & Services of Abgenix
Abgenix offers a comprehensive portfolio of products and services, including Pancreatic Cancer Drugs, Zika Virus Vaccines, and Cancer Treatments.
Drugs that block growth of pancreatic cancer cells
Vaccines aimed at fighting Zika virus infections
Treatments for various cancers including pancreatic types
Investors in Abgenix
Abgenix has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Amgen.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Developer of pharmaceutical products for treating multiple diseases | 1980 | amgen.com | Thousand Oaks, United States |
Investor details for Abgenix
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Abgenix
Abgenix has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include ImmGenics Pharmaceuticals.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Technology for antibody drug discovery. | immgenics.com | Vancouver, Canada | 1993 | Sep 2000 | $77M |
Complete acquisition details for Abgenix
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Abgenix
4 dated milestones of Abgenix across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Abgenix is founded.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires ImmGenics Pharmaceuticals.
- Exit Acquired by Amgen.
Competitors of Abgenix
Abgenix has 3 listed competitors in our database, 2 of them funded. They include BeiGene, Moderna and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of Abgenix
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Abgenix (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Abgenix
Abgenix was founded in 1996.
Abgenix is headquartered in Fremont, United States. It is registered at Fremont, California, United States.
Abgenix was a biopharmaceutical company focused on the discovery of fully human therapeutic antibodies for cancer and inflammatory diseases. Its products include Panitumumab, co-developed by Amgen is an IgG2 MAb which targets the epidermal growth factor receptor (EGFr), a protein that plays a role in cancer cell signaling. Its other product Denosumab is designed to target RANK Ligand, a protein that acts as the primary signal to promote bone removal. It claims to have potential in the treatment of a broad range of bone loss conditions including osteoporosis, treatment-induced bone loss, bone metastases, multiple myeloma, and rheumatoid arthritis. In December 2005, Amgen acquired Abgenix for around 2.2B.
Abgenix offers Pancreatic Cancer Drugs, Zika Virus Vaccines, and Cancer Treatments.
Abgenix has made 1 acquisition, including ImmGenics Pharmaceuticals.
Abgenix has 1 investor. Key investors include Amgen.
Yes. Abgenix was acquired by Amgen in December 2005.